Myo/Chiro 40:1 Capsule
Natural health product licensed in Canada
- Other names
- 40:1 RATIO MYO-INOSITOL + D-CHIRO-INOSITOL, Myo/Chiro 40:1
- Licence holder
- Augustine Inc. DBA Pink Stork
- NPN or DIN-HM
- 80147687
- Status
- Active licence
- Licence date
- 6 March 2026
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Myo-inositol Source : Inositol | 666.67 mg | Not calculated |
| D-Chiro-inositol Source : D-Chiro-inositol | 16.67 mg | Not calculated |
Non-medicinal ingredients
Poudre d'Oryza Sativa (Riz), Poudre d'enveloppes d'Oryza sativa (Riz), Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes | minimum: 18 years | 3 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps promote normal ovulatory function in women with PCOS. Helps/Aids in the management of polycystic ovarian syndrome (PCOS) by helping to restore normal ovarian function. Aids/Helps promote healthy glucose metabolism in those with PCOS. Aids/Helps in the management of PCOS's hormonal and metabolic conditions by promoting health glucose metabolism. Myo-inositol combined with D-chiro-inositol helps improve ovarian function in women with oligomenorrhea and polycystic ovaries. Helps support healthy sex hormone-binding globulin levels in women with PCOS. Helps promote/restore pregnancy rates/fertility in women under 36 years old with PCOS who undergo In Vitro Fertilization (IVF). Helps restore the number of high-quality oocytes in women with PCOS. Aids in the management of PCOS's hormonal and metabolic conditions. Myo-inositol helps decrease serum androgen concentrations, promotes healthy glucose metabolism and promotes insulin sensitivity in women with PCOS and aids in the management of PCOS hormonal and metabolic conditions.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80147687
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.